Compare Ascendis Pharma A/S (ASND) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Li Auto Inc — how do they compare? Ascendis Pharma A/S trades at $263.79 (market cap $17.74B), while Li Auto Inc trades at $12.22 (market cap $11.97B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.
| ASND | LI | |
|---|---|---|
Market Cap | $17.74B | $11.97B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $31.80 |
52-Week Low | $163.32 | $11.74 |
Enterprise Value | $18.11B | $888.72M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Li Auto (LI) trades at $12.10, down 1.6% with a bearish technical signal. Recent earnings show volatility with Q1 2026 missing estimates, while cash flow turned negative in 2025. The company faces intense competition and margin pressure, though analyst consensus remains cautiously optimistic with a $14.80 price target. Vehicle deliveries reached 30,895 in June 2026, indicating steady demand despite market headwinds.
Outlook hinges on execution of L series models and recovery from 2025-2026 trough years. Risks include aggressive discounting, regulatory challenges, and macroeconomic pressures in China's EV market. The stock presents a speculative opportunity if operational improvements materialize, but near-term volatility is expected.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
